ABout MDMA

James Allen serves as Sr. Vice President and Chief Financial Officer at B. Braun Medical Inc., where he leads all financial operations for the B. Braun Group of Companies in North America. His responsibilities include executive oversight of the Accounting, Tax, Procurement, Supply Chain, Logistics and IT departments.

Mr. Allen has more than 30 years of finance and management experience across a range of industries and financial disciplines. Prior to joining B. Braun, he served for 6 years as an operating company CFO with Steel Partners, where he led the implementation of multiple successful growth initiatives. In prior roles, Mr. Allen spent 15 years at Johnson & Johnson in a variety of business development and financial leadership roles in the Pharmaceutical and Medical Devices & Diagnostics sectors. He began his career at Amoco Corporation in roles including business development, internal auditing, brand marketing and sales. Mr. Allen holds an MBA from the Kellogg Graduate School of Management at Northwestern University, and a BS in Finance from the University of Maryland. He is a Certified Management Accountant.

Laurent Attias is Head of Corporate Development, Strategy, BD&L and M&A where he leads the development of long-term strategic plans for the Surgical and Vision Care franchises of Alcon and is responsible for the Alcon’s BD&L, M&A, partnerships and alliance activities, a role which he has held since 2015. Since 1994 when Mr. Attias joined Alcon, he has had various roles with increasing responsibility beginning with positions in Alcon’s Sales and Marketing functions and then holding the positions of Vice President, Refractive Sales and Marketing from 2002 to 2007; Vice President/General Manager of Alcon Canada from 2007 to 2009; Vice President, Central & Eastern Europe, Italy and Greece from 2009 to 2010; and President, Europe, Middle East and Africa (“EMEA”) from 2010 to 2012. From 2012 to 2015 as Senior Vice President of Global Commercial Franchises, Mr. Attias lead all commercial execution and product pipeline activities of Alcon’s Surgical, Pharmaceutical and Vision Care franchises.

Mr. Attias holds both a Bachelor of Business Administration in Marketing and a Master of Business Administration from Texas Christian University.

Quentin Blackford has served as a member of our board of directors since September 2023. Mr. Blackford currently serves as the President and Chief Executive Officer at iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare solutions company. Prior to iRhythm Technologies, Mr. Blackford served at Dexcom, Inc. from 2017 to 2021, first as Chief Financial Officer and then as Chief Operating Officer. Prior to Dexcom, Mr. Blackford served at Nuvasive, Inc. from 2009 to 2017, including as Chief Financial Officer and as Head of Strategy and Corporate Integrity from 2014 to 2017. Prior to 2009, Mr. Blackford served at Zimmer Biomet, Inc. (NYSE: ZBH) in various senior financial leadership positions. Since October 2017, Mr. Blackford also serves as a member of the board of directors of Alphatec Holdings, Inc. (NASDAQ: ATEC), where he serves on the compensation committee and audit committee. Mr. Blackford is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.

Todd J. Brinton, M.D., has been corporate vice president, advanced technology, and chief scientific officer, since 2019. Dr. Brinton has significant experience as a champion of cardiovascular innovation and has a strong patient focus as a tenured practicing clinical cardiologist. He has deep ties to the medical technology community as a founder, board member and advisor to several start-up companies, including his role as physician founder, board member, and chief medical officer of Shockwave Medical, Inc (SWAV). Dr. Brinton began his career as an engineer in the medical technology industry, ultimately becoming a director of clinical research and development, prior to entering medical school. Before joining Edwards, he was a clinical professor of medicine (cardiology) and adjunct professor of bioengineering at the Stanford University School of Medicine. He was an attending interventional cardiologist at both the Stanford University Medical Center and the Palo Alto VA Medical Center. Dr. Brinton also served as the fellowship director at the Stanford Byers Center for Biodesign from 2006 to 2019, where he mentored and directed numerous teams on the development of new technologies. In addition, he served as the co-director for both the graduate and executive education programs at the center during a similar time period. He is currently an Adjunct Professor of Medicine (Cardiology) at Stanford University as well as senior advisor and member of the Board for the Stanford Byers Center for Biodesign. He is extremely active in the American Heart Association serving as the Chair of the 2022 Bay Area Research Roundtable and the 2022 Orange County Heart & Stroke Ball. He currently serves on the AHA national research committee and Board of Directors for the AHA Western region. He also serves on the Board of Directors for the Medical Device Manufacturers Association and advisory boards for the Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center at UC Irvine. Dr. Brinton received his bachelor’s degree from the University of California, San Diego in biomedical engineering, and his medical degree from the Chicago Medical School at Rosalind Franklin University. He completed his internship, residency, and fellowships in cardiology and interventional cardiology at Stanford.

Mike Carrel joined AtriCure as President and Chief Executive Officer in 2012. Under his leadership, the company has consistently grown revenue at more than 20% per year and the employee base has grown from 200 to over 500 today. Additionally, he has established a patient first company culture, in which the company is investing in ground-breaking clinical trials for the treatment of Atrial Fibrillation and Left Atrial Appendage Management. In addition, during his tenure AtriCure has acquired two companies, Estech and nContact, who have brought leading ablation technologies to further AtriCure’s market position worldwide. Mr. Carrel also serves on the boards of Lombard Medical, the Medical Device Manufacturers Association (MDMA), and the American Heart Association Chapter in Minneapolis.

Mr. Carrel previously served as the President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company, from 2008 until 2012. He originally joined Vital Images in January 2005 as Chief Operating Officer and Chief Financial Officer. During his tenure at Vital Images, Mr. Carrel led the company to a leadership position in the healthcare and medical software industry. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and raised 100 million dollars in equity financings. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems, now part of Motorola. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Andrew I. Chang is President of Carl Zeiss Meditec USA, Inc., Head of Global Sales Ophthalmic Devices, Board Member for MicroOptx, ASCRS Foundation, Ophthalmology Foundation, Cataract Technologies Inc. and founding member of Vanguard Ophthalmology Society.

Andy’s breadth of experience across the ophthalmic industry in diagnostic and surgical devices, as well as pharmaceuticals has made him an exceptional leader in the industry. His understanding of the needs of the clinician and how technology can improve their work has successfully transitioned some of the ophthalmic industry’s most influential companies to the next level in market leadership. Through partnership with doctors from early-stage development to integrating and implementing cutting-edge technologies into daily clinical practice Andy has made significant contributions to the expansion of offerings for ophthalmic and optometric customers worldwide.

Prior to joining ZEISS, Andy was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Andy led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Andy held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.

Ryan joined NEA in 1996, and became a General Partner in 2004.He specializes in healthcare investments in the specialty pharma, medical device and healthcare information technology sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, ExploraMed III, ForHealth Technologies, Intrinsic Therapeutics, Neotract, PatientKeeper, Simplex Diabetic Supply, Spine Wave, Viacor and Vibrynt. Ryan also co-manages NEA’s investment in TriVascular2.Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan),FoxHollow Technologies (NASDAQ: FOXH), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.

Laura A. Francis has served as our Chief Executive Officer and a Director on our Board since April 2021. As our Chief Financial Officer since May 2015 and Chief Operating Officer since July 2019, Ms. Francis played a fundamental role in bringing the company public in October 2018 and building the operations of the business. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny (Nasdaq: PGNY), Promega Corporation, and Bruker Corporation (Nasdaq: BRKR). Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers. Ms. Francis has been a Director for Shockwave Medical (Nasdaq: SWAV) since January 2019, where she serves as Audit Committee Chair and Compensation Committee Member. She received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

Gregory A. Fredde is Executive Vice President of Business Development for Merit Medical Systems, Inc. headquartered in South Jordan, Utah. Since joining Merit Medical in 2003, Mr. Fredde has participated in nearly 100 transactions with a total transactional value of nearly $1 billion and contributing over $450 million in annual revenues. These transactions have included equity investments, distribution agreements, asset and stock purchases, and technology transfers.

Mr. Fredde has also led on-site integration teams for Merit’s acquisitions. These responsibilities have included consolidation of facilities, integration of retained employees, termination of previous business agreements, coordination of IT-based systems, and management of and compliance with ancillary agreement including CMAs, TSAs, and distribution agreements.

Mr. Fredde currently represents Merit on six corporate boards of directors in whose companies Merit is an investor.

Merit Medical is Utah’s largest home-grown medical device company with 6,000 worldwide employees in ten manufacturing facilities throughout the world including the United States., Mexico, Ireland, The Netherlands, France, Brazil, Australia, and Singapore. Since its founding in 1987, Merit’s annual revenues are projected to exceed $1 billion in 2019.

Prior to working with Merit, Mr. Fredde was President of the Utah Mining Association from 2001-2003. Mr. Fredde also served as Vice President of the Utah Taxpayers Association and has worked in a variety of local, state, and federal positions including the U.S. Department of State, State of Utah Community and Economic Development, and Ogden City’s Mayor’s Office.

Mr. Fredde graduated from the University of Utah with Bachelor of Science and Master of Arts degrees in Political Science.

Doug Godshall serves as Chairman of the Board of Directors for Saluda Medical and as Executive Chairman for Galvanize Therapeutics. Saluda is developing and commercializing disruptive neuromodulation systems using it’s novel Smartloop™ algorithm. Galvanize designs and develops Pulsed Electric Field Systems to achieve meaningful and lasting outcomes in the fields of oncology and chronic bronchitis. Mr. Godshall most recently served for 7 years as President and CEO of Shockwave Medical until its acquisition by Johnson and Johnson in May of 2024 for $13B. Shockwave developed and commercialized interventional tools to treat calcified structures throughout the cardiovascular system and devices to treat patients suffering from refractory angina. Prior to Shockwave, he served as President and Chief Executive Officer of HeartWare International, Inc., a leader in the LVAD market where he served for 10 years until the company was acquired by Medtronic in August of 2016 for $1.1B. Prior to HeartWare, he held various executive and leadership positions at Boston Scientific, including President of the Vascular Surgery Division, a member of Boston Scientific’s Operating Committee and had previously served as Vice President, Business Development where he was responsible for more than 70 transactions. Mr. Godshall holds an M.B.A. from Northeastern University and a BA in Economics from Lafayette College.